Comparative Pharmacology
Head-to-head clinical analysis: MENTAX versus XOLEGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX versus XOLEGEL.
MENTAX vs XOLEGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
Cholestyramine, the active ingredient in XOLEGEL, is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This prevents enterohepatic recirculation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver, thereby lowering serum low-density lipoprotein (LDL) cholesterol.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
Apply a thin layer to affected areas once daily. Maximum 60 g per week. Do not use on the face, axillae, or groin. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
The terminal elimination half-life is approximately 2.5 hours in adults based on intravenous data, but clinical relevance is minimal due to negligible systemic absorption after topical use.
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Following topical application, negligible systemic absorption occurs; any absorbed fraction is primarily eliminated via renal excretion as unchanged drug and metabolites. Biliary/fecal excretion is minimal.
Category C
Category C
Topical Antifungal
Topical Antifungal